Abattis Bioceuticals Corp
Abattis Bioceuticals Corp. operates as a life sciences and biotechnology company in Canada. The company develops and licenses natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets. It also provides Comfort, a cannabinoid enhanced nutraceutical for pain and inflammation; and Health-Canada licensed services for the cann… Read more
Abattis Bioceuticals Corp (ATTBF) - Net Assets
Latest net assets as of September 2019: $10.67 Million USD
Based on the latest financial reports, Abattis Bioceuticals Corp (ATTBF) has net assets worth $10.67 Million USD as of September 2019.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($19.26 Million) and total liabilities ($8.59 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $10.67 Million |
| % of Total Assets | 55.38% |
| Annual Growth Rate | N/A |
| 5-Year Change | 2137.8% |
| 10-Year Change | 2707.07% |
| Growth Volatility | 439.15 |
Abattis Bioceuticals Corp - Net Assets Trend (2008–2019)
This chart illustrates how Abattis Bioceuticals Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Abattis Bioceuticals Corp (2008–2019)
The table below shows the annual net assets of Abattis Bioceuticals Corp from 2008 to 2019.
| Year | Net Assets | Change |
|---|---|---|
| 2019-09-30 | $10.67 Million | -3.87% |
| 2018-09-30 | $11.10 Million | +1338.31% |
| 2017-09-30 | $771.48K | +267.76% |
| 2016-09-30 | $209.78K | -55.99% |
| 2015-09-30 | $476.68K | -89.73% |
| 2014-09-30 | $4.64 Million | +732.06% |
| 2013-09-30 | $558.02K | -10.50% |
| 2012-09-30 | $623.47K | +5.57% |
| 2011-09-30 | $590.60K | +55.42% |
| 2010-09-30 | $380.01K | -34.94% |
| 2009-09-30 | $584.12K | +1152.27% |
| 2008-09-30 | $-55.51K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Abattis Bioceuticals Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10167464100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2019)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $114.45 Million | 1033.20% |
| Other Comprehensive Income | $-185.66K | -1.68% |
| Total Equity | $11.08 Million | 100.00% |
Abattis Bioceuticals Corp Competitors by Market Cap
The table below lists competitors of Abattis Bioceuticals Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Vista Land & Lifescapes Inc Preferred Series 2B
PSE:VLL2B
|
$14.33K |
|
Green Giant Inc.
NASDAQ:GGEI
|
$14.35K |
|
G RENT SPA
F:7F3
|
$14.37K |
|
Uravi Defence and Technology Limited
NSE:URAVIDEF
|
$14.38K |
|
Nextgen
TA:NXGN
|
$14.32K |
|
450940
KQ:450940
|
$14.32K |
|
PURPOSE MARIJ.OPP. TR.UTS
F:43V
|
$14.32K |
|
Nabors Energy Transition Corp. II Warrant
NASDAQ:NETDW
|
$14.32K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Abattis Bioceuticals Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2018 to 2019, total equity changed from 11,487,406 to 11,077,279, a change of -410,127 (-3.6%).
- Net loss of 3,042,005 reduced equity.
- Other comprehensive income decreased equity by 2,185,250.
- Other factors increased equity by 4,817,128.
Equity Change Factors (2018 to 2019)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.04 Million | -27.46% |
| Other Comprehensive Income | $-2.19 Million | -19.73% |
| Other Changes | $4.82 Million | +43.49% |
| Total Change | $- | -3.57% |
Book Value vs Market Value Analysis
This analysis compares Abattis Bioceuticals Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-09-30 | $-0.14 | $0.00 | x |
| 2009-09-30 | $2.41 | $0.00 | x |
| 2010-09-30 | $0.07 | $0.00 | x |
| 2011-09-30 | $0.06 | $0.00 | x |
| 2012-09-30 | $0.06 | $0.00 | x |
| 2013-09-30 | $0.02 | $0.00 | x |
| 2014-09-30 | $0.08 | $0.00 | x |
| 2015-09-30 | $0.01 | $0.00 | x |
| 2016-09-30 | $0.01 | $0.00 | x |
| 2017-09-30 | $0.01 | $0.00 | x |
| 2018-09-30 | $0.04 | $0.00 | x |
| 2019-09-30 | $0.02 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Abattis Bioceuticals Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -27.46%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -852.40%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 1.74x
- Recent ROE (-27.46%) is above the historical average (-255.86%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 0.00% | 0.00% | 0.00x | 0.00x | $488.00 |
| 2009 | -10.85% | 0.00% | 0.00x | 1.29x | $-121.78K |
| 2010 | -199.76% | 0.00% | 0.00x | 2.14x | $-797.11K |
| 2011 | -240.10% | 0.00% | 0.00x | 1.22x | $-1.48 Million |
| 2012 | -159.17% | 0.00% | 0.00x | 2.13x | $-1.05 Million |
| 2013 | -197.57% | -6318.72% | 0.01x | 2.92x | $-1.16 Million |
| 2014 | -187.21% | -98049.37% | 0.00x | 1.46x | $-7.97 Million |
| 2015 | -519.71% | -4864.64% | 0.06x | 1.88x | $-4.56 Million |
| 2016 | -348.67% | 0.00% | 0.00x | 1.89x | $-2.41 Million |
| 2017 | -500.69% | 0.00% | 0.00x | 0.79x | $-7.79 Million |
| 2018 | -679.12% | -931940.11% | 0.00x | 0.99x | $-79.16 Million |
| 2019 | -27.46% | -852.40% | 0.02x | 1.74x | $-4.15 Million |
Industry Comparison
This section compares Abattis Bioceuticals Corp's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Abattis Bioceuticals Corp (ATTBF) | $10.67 Million | 0.00% | 0.81x | $14.33K |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |